Abstract
Hypereosinophilic syndrome (HES) treatment relies mainly on steroids and cytotoxic therapies. Mepolizumab has shown to be effective in reducing disease flares and FDA has approved its use at the dose of 300 mg every 4 weeks as add on therapy in HES patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
